• Corpus ID: 202685185

Tumor-specific uptake of fluorescent bevacizumab-IRDye 800 CW microdosing in patients with primary breast cancer

@inproceedings{Lamberts2019TumorspecificUO,
  title={Tumor-specific uptake of fluorescent bevacizumab-IRDye 800 CW microdosing in patients with primary breast cancer},
  author={Laetitia E. Lamberts and Maximillian Koch and Johannes S. de Jong and Arthur L.L. Adams and J{\"u}rgen Glatz and Mari{\"e}tte E. G. Kranendonk and Anton G. T. Terwisscha van Scheltinga and Liesbeth and Jansen and Jakob de Vries and Marjolijn N. Lub-de Hooge and Carolien P. Schröder and Jorritsma-Smit and Matthijs David Linssen and Esther A. de Boer and Bert van der Vegt and Sjoerd Elias and Sabrina Oliveira and Arjen J Witkamp and W. P. Th. M. Mali and Elsken van der Wall and Paul J. van Diest and Elisabeth G. E. de Vries and Vasilis Ntziachristos and Gooitzen M. van Dam},
  year={2019}
}
2 Citations

Tables from this paper

Current possibilities of peri-operative evaluation of the radicality of primary tumour resection in breast cancer patients treated with BCT (breast conserving treatment)
TLDR
The paper discusses some other currently available possibilities of perioperative evaluation of the radicality of primary tumour resection in breast cancer patients treated with BCT that may decrease the overall rate of revision surgeries.
A dual-labeled cRGD-based PET/optical tracer for pre-operative staging and intraoperative treatment of colorectal cancer.
TLDR
A single molecular imaging agent, ZW800F-cRGD-[89Zr]Zr-DFO, permits serial PET and NIRF imaging of colorectal tumors, with the latter permitting image-guided treatment intraoperatively.

References

SHOWING 1-10 OF 38 REFERENCES
111In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib
TLDR
RCC lesions were clearly delineated with 111In-bevacizumab scintigraphy and can be an attractive biomarker for response and needs further study.
A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies
TLDR
The novel method for quantification of the optical tracer IRDye800CW gives similar results as the reference method of gamma ray quantification, likely contributing to the selection of lead compounds that are the most promising for clinical translation.
Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer
TLDR
It is demonstrated for the first time that commercially available antibodies can be fluorescently labeled and safely administered to humans to identify cancer with sub-millimeter resolution, which has the potential to improve outcomes in clinical oncology.
VEGF-SPECT with ¹¹¹In-bevacizumab in stage III/IV melanoma patients.
Adjuvant trastuzumab in HER2-positive breast cancer.
TLDR
The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer and the risk-benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia.
Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use.
Antibody positron emission tomography imaging in anticancer drug development.
TLDR
This approach could potentially increase the power and value of early trials by improving patient selection, optimizing dose and schedule, and rationalizing observed drug responses.
...
...